JP2017531686A5 - - Google Patents

Download PDF

Info

Publication number
JP2017531686A5
JP2017531686A5 JP2017522496A JP2017522496A JP2017531686A5 JP 2017531686 A5 JP2017531686 A5 JP 2017531686A5 JP 2017522496 A JP2017522496 A JP 2017522496A JP 2017522496 A JP2017522496 A JP 2017522496A JP 2017531686 A5 JP2017531686 A5 JP 2017531686A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
treating
subject
compound
mounting serial
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017522496A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017531686A (ja
JP6545262B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2015/051024 external-priority patent/WO2016065461A1/en
Publication of JP2017531686A publication Critical patent/JP2017531686A/ja
Publication of JP2017531686A5 publication Critical patent/JP2017531686A5/ja
Application granted granted Critical
Publication of JP6545262B2 publication Critical patent/JP6545262B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017522496A 2014-10-27 2015-10-09 Ｒｉｐｋ２阻害剤およびそれを用いた癌の治療方法 Active JP6545262B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462068985P 2014-10-27 2014-10-27
US62/068,985 2014-10-27
PCT/CA2015/051024 WO2016065461A1 (en) 2014-10-27 2015-10-09 Ripk2 inhibitors and method of treating cancer with same

Publications (3)

Publication Number Publication Date
JP2017531686A JP2017531686A (ja) 2017-10-26
JP2017531686A5 true JP2017531686A5 (OSRAM) 2018-11-15
JP6545262B2 JP6545262B2 (ja) 2019-07-17

Family

ID=55856305

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017522496A Active JP6545262B2 (ja) 2014-10-27 2015-10-09 Ｒｉｐｋ２阻害剤およびそれを用いた癌の治療方法

Country Status (6)

Country Link
US (3) US10239881B2 (OSRAM)
EP (1) EP3212652B1 (OSRAM)
JP (1) JP6545262B2 (OSRAM)
CN (1) CN107454899B (OSRAM)
CA (1) CA2964282C (OSRAM)
WO (1) WO2016065461A1 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016065461A1 (en) 2014-10-27 2016-05-06 University Health Network Ripk2 inhibitors and method of treating cancer with same
WO2018052773A1 (en) * 2016-09-15 2018-03-22 Boehringer Ingelheim International Gmbh Pyridine and pyrazine compounds as inhibitors of ripk2
WO2018052772A1 (en) 2016-09-15 2018-03-22 Boehringer Ingelheim International Gmbh Heteroaryl carboxamide compounds as inhibitors of ripk2
JP6965083B2 (ja) * 2017-10-04 2021-11-10 公益財団法人微生物化学研究会 化合物、及び発光化合物
EP3897630B1 (en) * 2018-12-21 2024-01-10 Celgene Corporation Thienopyridine inhibitors of ripk2
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors
CN114957280B (zh) * 2021-12-31 2024-09-17 成都赜灵生物医药科技有限公司 噻吩[2,3-d]嘧啶衍生物及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
CA2402516A1 (en) * 2000-03-20 2001-09-27 Roopa Rai Non-amidine containing protease inhibitors
EP1182263A1 (en) 2000-08-11 2002-02-27 Evotec OAI AG Process for detecting threonine/serine kinase activity
US6426221B1 (en) 2001-08-01 2002-07-30 Isis Pharmaceuticals, Inc. Antisense modulation of RIP2 expression
WO2003042369A2 (en) 2001-11-13 2003-05-22 Phylos, Inc. Cellular kinase targets and inhibitors, and methods for their use
SI2215094T1 (sl) * 2007-11-15 2016-05-31 Ym Biosciences Australia Pty Ltd N vsebujoče heterociklične spojine
NZ590500A (en) 2008-08-16 2012-06-29 Genentech Inc Azaindole inhibitors of iap
WO2010046215A2 (en) 2008-10-21 2010-04-29 Syngenta Participations Ag Diaza-indole derivatives and their use as fungicides
WO2011079231A1 (en) * 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
ES2552977T3 (es) * 2010-05-07 2015-12-03 Glaxosmithkline Intellectual Property Development Limited Amino-quinolinas como inhibidores de quinasa
US8889684B2 (en) * 2011-02-02 2014-11-18 Boehringer Ingelheim International Gmbh Azaindolylphenyl sulfonamides as serine/threonine kinase inhibitors
CN103857288B (zh) 2011-03-04 2016-09-21 葛兰素史密斯克莱知识产权发展有限公司 作为激酶抑制剂的氨基-喹啉
WO2013078254A1 (en) 2011-11-22 2013-05-30 Array Biopharma Inc. Bicyclic heteroaryl derivatives as kinase inhibitors
WO2016065461A1 (en) 2014-10-27 2016-05-06 University Health Network Ripk2 inhibitors and method of treating cancer with same

Similar Documents

Publication Publication Date Title
JP2016028092A5 (OSRAM)
CY2023027I2 (el) Ενωσεις πυριμιδινοδιονης εναντι καρδιακων παθησεων
JP2016065085A5 (OSRAM)
JP2016502162A5 (OSRAM)
JP2017531686A5 (OSRAM)
IL261479A0 (en) Orally administrable composition
JP2015503422A5 (OSRAM)
JP2014221779A5 (OSRAM)
JP2016028081A5 (OSRAM)
LT3513809T (lt) Medicininė kompozicija, apimanti tivozanibą
JP2015125255A5 (OSRAM)
JP2016535100A5 (OSRAM)
JP2015528502A5 (OSRAM)
HUE056006T2 (hu) Kombináció Parkinson-kór kezelésére
JP2017537928A5 (OSRAM)
LT3390390T (lt) Bipirazolilo dariniai, tinkami naudoti autoimuninių ligų gydymui
JP2016540026A5 (OSRAM)
JP2016540019A5 (OSRAM)
JP2015173751A5 (OSRAM)
JP2015016294A5 (OSRAM)
JP2013231052A5 (OSRAM)
JP2017528459A5 (OSRAM)
HUE050565T2 (hu) Pirazolotiazol vegyület és azt tartalmazó gyógyszer
JP2016053220A5 (OSRAM)
JP2016214401A5 (OSRAM)